PATENT CLAIM ANALYSIS

Application Number: 15969519
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["544", "184000"]

Abstract:
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.

Claim (Index 17):
The method of  claim 15 , wherein the compound is 2-chloro-N-[(1 S)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 93.0
- Lexical Diversity: 1.19231
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13915702', '13019718', '14918879', '13793864', '11942130']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8479369478698021
- 35 USC 102 Novelty (BERT): 0.5811005112481407
- Combined Prediction Score: 0.821253304207636
- Mean Citation Score: 474.331564
- Max Citation Score: 516.1561
- Similarity Product: 422.8163303699851

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test